Methods Patients were prospectively enrolled between November 2014 and March 2017,
after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 …

Background Infliximab biosimilars have become available for treatment of inflammatory
bowel disease (IBD). However, data showing long‐term safety and effectiveness of …

Background and Aim A biosimilar of infliximab, CT‐P13 (Remsima®) has the potential to
reduce treatment costs and enhance access to biological therapy for inflammatory bowel …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

Nearly 20 years ago, biologic therapy was intro-duced for the treatment of Crohn's disease
(CD) and has since revolutionized the treatment of inflammatory bowel disease (IBD). The …

Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel
disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its …

Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients
with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients …

Abstract Background The NOR-SWITCH main and extension trials demonstrated that
switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six …

Biological drugs or biopharmaceutical products, manufactured with or from living organisms
using biotechnology, have represented a therapeutic revolution for the control of …